# Project 1

> **NIH NIH U19** · MAYO CLINIC ROCHESTER · 2020 · $380,810

## Abstract

ABSTRACT – ARTFL LEFFTDS Longitudinal FTLD: Project 1
Frontotemporal lobar degeneration (FTLD) is the overall term for a group of devastating neurodegenerative
disorders that have a profound effect on the lives of patients and their families. Research in FTLD is entering
an exciting period as potential disease-modifying drugs are being developed. One highly attractive approach
for therapy is to start treatment before symptoms occur. However, FTLD is currently almost always diagnosed
long after symptoms have begun, when the disease has already had profound effects on the brain. About
twenty percent of FTLD is due to autosomal dominant mutations, most commonly in the MAPT, GRN, or
C9orf72 genes (familial, or f-FTLD). Mutation carriers can be identified before the onset of dementia, and are
therefore critical for studies that would seek to delay or prevent symptoms. Intervention studies in f-FTLD will
require unique approaches for tracking the effects of treatment. First, they must choose measures that
demonstrate that an intervention is resulting in clinical benefit, even in people who are experiencing few if any
symptoms. Second, they must show that the treatment prevents or delays the onset of symptoms. However,
the age when a mutation carrier will develop dementia varies dramatically in f-FTLD, and there are no reliable
markers for predicting age of onset. Without such predictive tools, it is impossible to target patients who are
approaching symptom onset and calculate how many people would be needed for a study of symptom
prevention. The overall goal of this project is to prepare for clinical trials in f-FTLD by developing better
methods for selecting participants and for tracking disease burden to demonstrate treatment effects. The
project will pursue the following specific aims: 1) To identify the best clinical and imaging measures for tracking
disease burden in mutation carriers who are asymptomatic (FTLD-CDR=0), or mildly symptomatic (FTLD-
CDR=0.5), 2) To develop a multimodal risk score to predict worsening symptoms in asymptomatic or mildly
symptomatic mutation carriers using baseline clinical, genetic, protein biomarker and imaging data, and 3) To
quantify the value of tracking change in cortical volume over one year for predicting future worsening of
symptoms in asymptomatic or mildly symptomatic mutation carriers.

## Key facts

- **NIH application ID:** 10017895
- **Project number:** 5U19AG063911-02
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** HOWARD J ROSEN
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $380,810
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10017895

## Citation

> US National Institutes of Health, RePORTER application 10017895, Project 1 (5U19AG063911-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10017895. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*